Inozyme Pharma Announces Investor and Analyst Event and Highlights 2022 Progress
– Company to share topline data from ongoing Phase 1/2 trials of INZ-701 in ENPP1…
Year: 2023
CENTOGENE and Denali Therapeutics Extend World’s Largest Observational Study on Parkinson’s Disease Genetics
Working together to deliver data-driven, informative genotyping answers to accelerate and de-risk drug discovery, development,…
SciSparc Signs Agreement to Conduct its Clinical Trial in Autism Spectrum Disorder with Soroka Medical Center
Ethics Committee and Israeli Ministry of Health approvals already received for the Company’s study with…
Coherus Agrees to Acquire Exclusive U.S. Commercial Rights to Eylea® Biosimilar FYB203 from Klinge Biopharma
Additional Growth Driver Projected to Significantly Increase Mid-to-Long Term Revenue Potential REDWOOD CITY, Calif., Jan….
Editas Medicine Announces Strategic Updates and Portfolio Reprioritization
Strategic reprioritization of portfolio to focus on hemoglobinopathies and in vivo gene editing Discontinuing internal…
Outlook Therapeutics® to Present at the Virtual Investor 2023 Companies to Watch Event
Live video webcast presentation on Tuesday, January 17th at 11:00 AM ET ISELIN, N.J., Jan….
AIM ImmunoTech Broadens Patent Portfolio with New Netherlands Utility Patent Covering Ampligen® and Other AIM-Developed dsRNA Products to Include Rugged dsRNA for Use in COVID-19 Treatment or Prevention
OCALA, Fla., Jan. 09, 2023 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or…
Crinetics Pharmaceuticals to Present Corporate and Clinical Update at 41st Annual J.P. Morgan Healthcare Conference
Efforts to further increase commercial readiness ongoing as Phase 3 PATHFNDR trials of paltusotine in…
Denali Therapeutics Announces Key Anticipated 2023 Milestones for Its Therapeutic Portfolio for Neurodegeneration and Lysosomal Storage Diseases
Four programs expected to progress in late-stage clinical studies for MPS II (Hunter syndrome), ALS,…
Calithera Biosciences Announces Board Approval of Complete Liquidation and Dissolution
SOUTH SAN FRANCISCO, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) — Calithera Biosciences, Inc. (Nasdaq: CALA),…
Helsinn announces the appointment of Dr Melanie Rolli as Group Chief Executive Officer
Helsinn announces the appointment of Dr Melanie Rolli as Group Chief Executive Officer – Giorgio…
ENA Respiratory Awarded $4.38 Million U.S. Department of Defense Agreement to Fund Development of Broad-Spectrum Antiviral INNA-051
— Goal is to add new medical countermeasure (MCM) against known and emerging viral respiratory…
AmMax Bio Enters into an Exclusive Option Agreement with Evopoint Biosciences to License a Next Generation Antibody Drug Conjugate (ADC) for the Treatment of Solid Tumors
This novel ADC is expected to have a wider therapeutic index and superior clinical profile…
TFF Pharmaceuticals Announces the Appointment of Zamaneh Mikhak, M.D. as Chief Medical Officer
FORT WORTH, Texas, Jan. 09, 2023 (GLOBE NEWSWIRE) — TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a…
Selecta Biosciences Provides Business Update and Outlook for 2023
– Expected topline data for Phase 3 DISSOLVE I & II programs of SEL-212 in…
Cogent Biosciences Announces Planned 2023 Milestones for Bezuclastinib and Emerging Portfolio of Selective and Potent Targeted Cancer Therapeutics
Demonstrate significant progress toward leadership in Systemic Mastocytosis (SM), including mid-year Part 1 results from…
Vaccinex Announces First Patient Dosed with Anti-CCR8 Antibody Licensed to Surface Oncology
Surface Oncology initiates clinical trial with antibody discovered using Vaccinex’s ActivMAb® Antibody Discovery Platform ROCHESTER,…
Biomea Fusion to Present at 41st Annual J.P. Morgan Healthcare Conference and Highlight 2023 Corporate Milestones
REDWOOD CITY, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) — Biomea Fusion, Inc. (Nasdaq: BMEA), a…
Kiniksa Pharmaceuticals Provides Corporate and Portfolio Update
– ARCALYST® (rilonacept) Q4 2022 and full-year 2022 net product revenue of $39.9 million and…
ORIC Pharmaceuticals Provides Corporate Update and Highlights Key Upcoming Milestones
Initial Phase 1b data for three ongoing clinical trials expected in second half of 2023: ORIC-533…